Creating new treatments to enhance cancer immunotherapy effectiveness
Development of First-in-Class RIPK1 Degraders to Improve Cancer Immunotherapies
This study is looking at new drugs that can help make cancer treatments work better for patients who haven't had success with current therapies by targeting a protein called RIPK1, which affects how cancer cells react to the immune system.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Baylor College of Medicine NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-10877801 on NIH RePORTER |
What this research studies
This research focuses on developing innovative drugs that target a protein called RIPK1, which plays a crucial role in how cancer cells respond to immunotherapy. By understanding how RIPK1 affects cell survival and immune responses, the researchers aim to improve treatment outcomes for patients who currently do not respond to existing cancer therapies. The approach involves creating degraders that can effectively eliminate RIPK1 in cancer cells, potentially making tumors more susceptible to immunotherapy. Patients may be monitored for changes in their tumor microenvironment and overall response to treatment.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with advanced cancer who have not responded to current immunotherapy treatments.
Not a fit: Patients with early-stage cancer or those who have not yet undergone immunotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer treatments for patients who are currently non-responders to immunotherapy.
How similar studies have performed: Other studies have shown promising results in targeting RIPK1 to enhance cancer treatment, indicating that this approach has potential based on previous findings.
Where this research is happening
Houston, United States
- Baylor College of Medicine — Houston, United States (Active)
Researchers
- Principal investigator: Wang, Jin — Baylor College of Medicine
- Study coordinator: Wang, Jin
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.